Risk prediction 283 items

Studies

• Lp(a)FRONTIERS APHERESIS: pelacarsen replaces lipoprotein apheresis in 25 of 26 patients (Parhofer et al., EHJ 2026)Eur Heart J · July 2026 9
• Inflammation, cholesterol, Lp(a) and 30-year cardiovascular outcomes in women (Ridker et al., NEJM 2024)N Engl J Med · December 2024 8
• Lp(a) and incident ASCVD in 460,506 UK Biobank participants (Patel et al., ATVB 2021)Arterioscler Thromb Vasc Biol · January 2021 8
• Coronary artery calcium still stratifies risk in people with elevated Lp(a): a four-cohort study (Bhatia et al., JACC 2026)J Am Coll Cardiol · May 2026 7
• Thirty-year cardiovascular risk in healthy women by Lp(a) threshold: the Women's Health Study (Nordestgaard AT et al., JAMA Cardiol 2026)JAMA Cardiol · February 2026 7
• Only 13 percent of coronary patients worldwide would meet a 150 nmol/L trial threshold: INTERASPIRE (Barkas et al., JACC 2025)J Am Coll Cardiol · June 2025 7
• Lp(a) raises cardiovascular risk regardless of hs-CRP, in primary and secondary prevention (Small et al., JAMA Cardiol 2024)JAMA Cardiol · April 2024 7
• NLA focused update 2024: measure Lp(a) at least once in every adult, with three risk bands (Koschinsky et al., J Clin Lipidol 2024)J Clin Lipidol · January 2024 7
• Aspirin benefits older adults with Lp(a)-raising genotypes in primary prevention: ASPREE (Lacaze et al., JACC 2022)J Am Coll Cardiol · October 2022 7
• High Lp(a) accelerates low-attenuation (necrotic core) plaque progression on serial CT angiography (Kaiser et al., JACC 2022)J Am Coll Cardiol · January 2022 7
• Lp(a) lowering of about 50 mg/dL may be needed for a 20 percent MACE reduction in secondary prevention (Madsen et al., ATVB 2020)Arterioscler Thromb Vasc Biol · January 2020 7
• NLA scientific statement: use of Lp(a) in clinical practice, a biomarker whose time has come (Wilson et al., J Clin Lipidol 2019)J Clin Lipidol · January 2019 7
• Five years of lipoprotein apheresis for Lp(a)-associated disease: the German prospective follow-up (Roeseler et al., ATVB 2016)Arterioscler Thromb Vasc Biol · September 2016 7
• High Lp(a) as a possible cause of clinical familial hypercholesterolaemia (Langsted et al., Lancet Diabetes Endocrinol 2016)Lancet Diabetes Endocrinol · July 2016 7
• IL-6 modifies Lp(a)-associated coronary risk but not aortic stenosis risk: UK Biobank (JAMA Cardiol 2026)JAMA Cardiol · August 2026 6
• Regular aspirin use and lower incidence of aortic valve calcium and severe stenosis in people with high Lp(a): MESA (Razavi et al., EHJ 2026)Eur Heart J · February 2026 6
• Lp(a) and interleukin-6 are independent, additive predictors of coronary events: MESA and UK Biobank (Bhatia et al., JACC 2025)J Am Coll Cardiol · November 2025 6
• LDL-C, Lp(a) and hs-CRP are independent and synergistic predictors of MACE, on and off statins: UK Biobank (Markus et al., EHJ 2025)Eur Heart J · October 2025 6
• One-time LDL-C, hs-CRP and Lp(a) screening predicts 20-year events in European men and women: EPIC-Norfolk (Kraaijenhof, Nurmohamed et al., EHJ 2025)Eur Heart J · October 2025 6
• PREVENT equations perform well but Lp(a) adds independent risk, most in borderline- and low-risk people: MESA and UK Biobank (Bhatia et al., JAMA Cardiol 2025)JAMA Cardiol · August 2025 6
• Elevated Lp(a) in 2.9 million Chinese adults and its association with multisite subclinical atherosclerosis (Man et al., JACC 2025)J Am Coll Cardiol · June 2025 6
• After stopping olpasiran, Lp(a) stays 40 to 50 percent below baseline for nearly a year: OCEAN(a)-DOSE extension (O'Donoghue et al., JACC 2024)J Am Coll Cardiol · August 2024 6
• Aspirin use and lower CHD events in people with Lp(a) above 50 mg/dL: MESA (Bhatia et al., JAHA 2024)J Am Heart Assoc · February 2024 6
• Finding very high Lp(a): the case for routine assessment (Nurmohamed et al., Eur J Prev Cardiol 2022)Eur J Prev Cardiol · May 2022 6
• Lp(a) measurement issues: a mountain out of a molehill? (Kronenberg, Atherosclerosis 2022)Atherosclerosis · May 2022 6
• 2021 Canadian Cardiovascular Society dyslipidaemia guidelines: Lp(a) once in a lifetime (Pearson et al., Can J Cardiol 2021)Can J Cardiol · August 2021 6
• Genetically elevated Lp(a) shortens parental lifespan and health span (Arsenault et al., JAMA Netw Open 2020)JAMA Netw Open · February 2020 6
• Alirocumab cuts cardiovascular events regardless of sex, with a larger benefit at higher baseline Lp(a) in women, ODYSSEY OUTCOMES (J Clin Lipidol 2024)J Clin Lipidol · January 2024 9
• Copenhagen General Population Study shows relative ASCVD risk per 50 mg/dL higher Lp(a) remains similar in adults aged 80 to 100 years (Circulation 2026)Circulation · August 2026 8
• Adding Lp(a) to ApoB improves aortic-stenosis risk prediction, especially in men, UK Biobank cohort of 365,771 (Eur J Prev Cardiol 2026)Eur J Prev Cardiol · May 2026 8
• Lp(a), remnant cholesterol and hsCRP each independently add to MI risk prediction, UK Biobank cohort of 306,183 (Prog Cardiovasc Dis 2026)Prog Cardiovasc Dis · April 2026 8
• An Lp(a)-linked proteomic signature predicts cardiovascular disease beyond Lp(a) alone in young adults, CARDIA study of 3,920 with UK Biobank replication (J Clin Invest 2026)J Clin Invest · April 2026 8
• Machine learning finds 26-253% more elevated-Lp(a) cases per test than universal screening, model of 438,579 (Eur J Prev Cardiol 2026)Eur J Prev Cardiol · March 2026 8
• Lp(a) causally affects coronary disease and HbA1c but not diabetes risk, UK Biobank phenome-wide MR of 425,677 (JACC Adv 2026)JACC Adv · March 2026 8
• High Lp(a) and high BMI jointly maximize ASCVD risk, Danish and UK Biobank cohorts of 512,687 (Eur J Prev Cardiol 2026)Eur J Prev Cardiol · February 2026 8
• Very high Lp(a) predicts earlier heart attack and 16-fold higher recurrent MI risk, matched cohort of 446 (JACC Adv 2026)JACC Adv · January 2026 8
• ABO blood group A or B sharpens Lp(a)'s link to MACE in chronic coronary syndrome, replicated across two cohorts totalling over 15,500 patients (MedComm (2020) 2025)MedComm (2020) · November 2025 8
• A machine-learning model adding Lp(a) predicts 1-year ASCVD risk better than smoking or diabetes status, validated in 53,930 patients (JACC Adv 2025)JACC Adv · October 2025 8
• Factorial Mendelian randomisation in 385 917 UK Biobank participants finds Lp(a) lowering benefits add to, not multiply, LDL-C and lifestyle effects (Int J Epidemiol 2025)Int J Epidemiol · February 2025 8
• REFERCHOL study of 2,979 heterozygous FH patients finds extreme Lp(a) confers cardiovascular risk equivalent to secondary prevention (J Clin Lipidol 2025)J Clin Lipidol · January 2025 8
• High Lp(a) triples peripheral artery disease and doubles abdominal aortic aneurysm risk, confirmed genetically, in 108,146 Danes (J Am Coll Cardiol 2023)J Am Coll Cardiol · December 2023 8
• Mass, molar and mass-spectrometry Lp(a) assays predict cardiovascular risk and alirocumab benefit equally in 11,970 ODYSSEY OUTCOMES patients (Circulation 2024)Circulation · August 2023 8
• Lp(a) predicts faster aortic valve stenosis progression and higher mortality, confirmed genetically via two LPA variants, in a meta-analysis of 163,139 subjects (Cardiovasc Res 2023)Cardiovasc Res · July 2023 8
• Lp(a) and family history of cardiovascular disease combine to raise heart failure risk by 42% in 299,158 UK Biobank adults (J Lipid Res 2023)J Lipid Res · June 2023 8
• Lp(a) above 50 mg/dL raises cardiovascular mortality risk by 83% independent of LDL cholesterol, in 275,430 Korean adults (Eur J Prev Cardiol 2023)Eur J Prev Cardiol · March 2023 8
• Every 50 mg/dL rise in Lp(a) raises cardiovascular death risk by up to 31%, a dose-response meta-analysis of 957,253 people across 75 studies (Eur J Epidemiol 2023)Eur J Epidemiol · January 2023 8
• High Lp(a) in youth (ages 9-24) doubles the risk of adult cardiovascular disease decades later, pooled data from the Young Finns Study and Bogalusa Heart Study (Circulation 2023)Circulation · November 2022 8
• Lp(a) of 180 mg/dL carries the same heart attack risk as genetically diagnosed familial hypercholesterolaemia, in 69,644 Danes followed 42 years (J Am Coll Cardiol 2022)J Am Coll Cardiol · November 2022 8
• Lp(a) causally raises atrial fibrillation risk largely independent of atherosclerosis, a Mendelian randomisation study of 435,579 UK Biobank participants (J Am Coll Cardiol 2022)J Am Coll Cardiol · April 2022 8
• Extreme Lp(a) and extreme body weight together carry a 3.5-fold risk of calcific aortic valve disease, in 69,988 Danes (J Am Coll Cardiol 2022)J Am Coll Cardiol · February 2022 8
• Lp(a) above 175 nmol/L explains 3% of population cardiovascular disease burden, and lowering it 80% could cut CHD risk by 24%, an analysis of 413,734 UK Biobank participants (Eur J Prev Cardiol 2022)Eur J Prev Cardiol · February 2022 8
• A newly discovered LPA splicing variant lowers Lp(a) by 13.6 mg/dL and cuts coronary disease risk by 9%, found in 4,673 Germans and validated in 440,234 UK Biobank participants (J Am Coll Cardiol 2021)J Am Coll Cardiol · August 2021 8
• Elevated Lp(a) triples stroke-recurrence risk in patients under 60, the BIOSIGNAL study of 1,733 acute stroke patients (Eur Heart J 2021)Eur Heart J · June 2021 8
• Measured Lp(a) and a 43-variant genetic risk score predict cardiovascular disease equally well, but adding either only modestly improves standard risk scores, in 374,099 UK Biobank participants (JAMA Cardiol 2021)JAMA Cardiol · March 2021 8
• Standard LDL-C tests only predict cardiovascular risk because they secretly include Lp(a) cholesterol, reclassifying up to 41% of patients once corrected, an analysis spanning 531,144 lab patients (J Am Heart Assoc 2020)J Am Heart Assoc · November 2020 8
• Elevated Lp(a) raises cardiac event risk by 78% in CAD patients, a meta-analysis of 17 studies and 283,328 patients (Lipids Health Dis 2019)Lipids Health Dis · July 2019 8
• Higher Lp(a) linearly predicts faster aortic valve stenosis progression, especially in younger patients, an ASTRONOMER trial secondary analysis of 220 patients (JAMA Cardiol 2018)JAMA Cardiol · December 2018 8
• Elevated Lp(a) risk fades when LDL cholesterol is below 2.5 mmol/L, an EPIC-Norfolk and Copenhagen City Heart Study analysis (Eur Heart J 2018)Eur Heart J · July 2018 8
• Lp(a) predicts cardiovascular risk in women only when total cholesterol is high, an analysis of over 24,000 Women's Health Study participants plus WHI and JUPITER cohorts (J Am Coll Cardiol 2018)J Am Coll Cardiol · July 2018 8
• Lp(a) above 50 mg/dL confers over 10-fold higher risk of heart attack, stroke or amputation in patients with existing artery disease, the FRENA registry of 1503 patients (Atherosclerosis 2018)Atherosclerosis · July 2018 8
• Lp(a) predicts continued carotid plaque progression despite intensive LDL-lowering therapy, an AIM-HIGH trial imaging substudy of 152 patients (Arterioscler Thromb Vasc Biol 2018)Arterioscler Thromb Vasc Biol · January 2018 8
• Lp(a) in the top 25% raises abdominal aortic aneurysm risk by 57%, the ARIC study of 13,683 adults over 22 years (Atherosclerosis 2018)Atherosclerosis · November 2017 8
• LPA gene variants triple Lp(a) levels, and the highest Lp(a) quartile raises heart attack risk by 49% in chronic kidney disease, the CRIC Study of 3744 patients (Arterioscler Thromb Vasc Biol 2017)Arterioscler Thromb Vasc Biol · August 2017 8
• Lp(a) risk is highest in Southern Europe and in people with diabetes, the BiomarCaRE consortium study of 56,804 Europeans (Eur Heart J 2017)Eur Heart J · August 2017 8
• Lp(a) and its gene variants predict coronary disease severity but not mortality once heart disease is established, a study of 3313 LURIC patients validated in over 106 000 (Lancet Diabetes Endocrinol 2017)Lancet Diabetes Endocrinol · May 2017 8
• 48 gene variants and a rare SNP with an odds ratio of 1.73 for CAD found in the largest Lp(a) genome-wide study yet, a meta-analysis of 13,781 people (J Lipid Res 2017)J Lipid Res · May 2017 8
• Both smaller apo(a) isoform size and higher Lp(a) concentration independently cause coronary heart disease, a Mendelian randomisation study of over 184 000 people (Lancet Diabetes Endocrinol 2017)Lancet Diabetes Endocrinol · April 2017 8
• Ideal cardiovascular health cuts the excess risk from high Lp(a) by two-thirds, the EPIC-Norfolk study of 14,051 adults (Atherosclerosis 2017)Atherosclerosis · November 2016 8
• High Lp(a) predicts death from infection in younger dialysis patients with diabetes, the 4D Study post hoc analysis of 1255 patients (Nephrol Dial Transplant 2016)Nephrol Dial Transplant · January 2016 8
• The standard 30 mg/dL Lp(a) cutoff misses risk in white and Hispanic adults, who need the 50 mg/dL threshold instead, the MESA study across 4 races (Arterioscler Thromb Vasc Biol 2015)Arterioscler Thromb Vasc Biol · February 2015 8
• Lp(a) improves 15-year cardiovascular risk prediction, especially for people at intermediate risk, the Bruneck Study of 826 adults (J Am Coll Cardiol 2014)J Am Coll Cardiol · September 2014 8
• A common LPA null allele carried by 3% of people lowers Lp(a) and cuts coronary disease risk, the PROCARDIS study of 4073 CAD cases and 4225 controls (Arterioscler Thromb Vasc Biol 2014)Arterioscler Thromb Vasc Biol · June 2014 8
• Lp(a) above 30 mg/dL triples the risk of death or heart attack after bypass surgery, a Russian study of 356 patients followed 15 years (Atherosclerosis 2014)Atherosclerosis · June 2014 8
• Lp(a) barely changes after eating or with inflammation, and still predicts heart disease regardless, a Danish study of 34 829 people (Atherosclerosis 2014)Atherosclerosis · February 2014 8
• Pro-inflammatory IL-1 genotype raises coronary disease risk from oxidized phospholipids seven-fold in younger patients, a study of 499 patients (J Am Coll Cardiol 2014)J Am Coll Cardiol · February 2014 8
• Statins do not lower Lp(a), yet Lp(a) still predicts residual cardiovascular risk after statin therapy, a JUPITER trial analysis of 9612 participants (Circulation 2014)Circulation · November 2013 8
• Lp(a) predicts heart disease risk in secondary prevention only when LDL cholesterol is elevated, a meta-analysis of 18,978 patients (J Am Coll Cardiol 2014)J Am Coll Cardiol · October 2013 8
• Lp(a) above 73 mg/dL predicts future heart attacks in patients with stable coronary disease, the LIPID trial substudy of 7863 patients (Arterioscler Thromb Vasc Biol 2013)Arterioscler Thromb Vasc Biol · October 2013 8
• Niacin lowers Lp(a) by 21% but does not reduce cardiovascular events, the AIM-HIGH trial analysis of apolipoproteins and Lp(a) (J Am Coll Cardiol 2013)J Am Coll Cardiol · August 2013 8
• Extreme Lp(a) or its gene variants correctly reclassify up to 23% of heart attack risk predictions, a Danish study of 8720 people (J Am Coll Cardiol 2013)J Am Coll Cardiol · January 2013 8
• Lp(a) predicts peripheral artery disease and coronary disease but not stroke, the EPIC-Norfolk study of 18 720 adults (Arterioscler Thromb Vasc Biol 2012)Arterioscler Thromb Vasc Biol · October 2012 8
• Lp(a) genetically drives atherosclerotic narrowing but not venous blood clots, a Mendelian randomisation study of 41,231 people (Arterioscler Thromb Vasc Biol 2012)Arterioscler Thromb Vasc Biol · April 2012 8
• Lp(a) doubles coronary disease risk in men but not women, with apo(a) isoform size adding no predictive value, the Framingham Offspring Study (J Lipid Res 2011)J Lipid Res · April 2011 8
• Oxidized phospholipids potentiate Lp(a) coronary risk two-fold when combined with high phospholipase A2 activity, an EPIC-Norfolk study of 763 cases and 1397 controls (J Am Coll Cardiol 2010)J Am Coll Cardiol · September 2010 8
• Lp(a) predicts coronary revascularization need only when LDL cholesterol is above 70 mg/dL, a study of 2769 angiography patients (J Lipid Res 2010)J Lipid Res · July 2010 8
• A genome-wide study finds at least 6 genes beyond LPA that independently affect Lp(a) levels, a study of 386 people (J Lipid Res 2009)J Lipid Res · January 2009 8
• Hormone replacement therapy erases Lp(a) ability to predict cardiovascular risk in women, a study of 27,736 participants (J Am Coll Cardiol 2008)J Am Coll Cardiol · July 2008 8
• Extreme Lp(a) predicts a 3- to 4-fold higher heart attack risk, with absolute 10-year risk up to 35% in high-risk men, the Copenhagen City Heart Study of 9330 people (Circulation 2008)Circulation · December 2007 8
• Oxidized phospholipids on Lp(a) predict 10-year cardiovascular events, amplified by a related enzyme activity, the Bruneck study of 765 people (Arterioscler Thromb Vasc Biol 2007)Arterioscler Thromb Vasc Biol · May 2007 8
• Only extremely high Lp(a) above the 90th percentile raises cardiovascular risk in women, the Women's Health Study of 27,791 participants (JAMA 2006)JAMA · September 2006 8
• Lp(a) predicts cardiovascular events but not cognitive decline in the elderly, the PROSPER study of 5732 people (Atherosclerosis 2005)Atherosclerosis · January 2005 8
• A specific LPA gene haplotype raises heart attack risk in women independent of Lp(a) level, a German study of 834 MI patients and 1548 controls (Circulation 2003)Circulation · February 2003 8
• Lp(a) raises heart disease risk especially in men with high LDL cholesterol, the PRIME Study of 9133 men (Atherosclerosis 2002)Atherosclerosis · August 2002 8
• Lp(a) predicts heart disease risk in both sexes, with much stronger overall risk prediction in women, the ARIC study of 12,339 people (Circulation 2001)Circulation · September 2001 8
• Lp(a) triples coronary risk in men with low HDL cholesterol, the PROCAM study of 788 men (J Am Coll Cardiol 2001)J Am Coll Cardiol · February 2001 8
• Lp(a) in the top third raises coronary heart disease risk by 60%, a meta-analysis of 27 prospective studies (Circulation 2000)Circulation · September 2000 8
• Estrogen plus progestin lowers Lp(a) and benefits women with high baseline Lp(a) most, the HERS trial of 2763 postmenopausal women (JAMA 2000)JAMA · April 2000 8
• Lp(a) concentrations vary considerably over 24 months in high cardiovascular risk patients with hypertriglyceridemia on statins (REDUCE-IT) (J Clin Lipidol 2026)J Clin Lipidol · September 2026 7
• Lp(a) prevalence and screening thresholds vary across high-risk groups in the Rotterdam Study (Eur J Prev Cardiol 2026)Eur J Prev Cardiol · August 2026 7
• Lp(a) at acute coronary syndrome presentation predicts Stanford type A aortic dissection (Nutr Metab Cardiovasc Dis 2026)Nutr Metab Cardiovasc Dis · August 2026 7
• Lp(a) and a 43-variant genetic risk score predict sudden cardiac death in older men with high triglycerides, UK Biobank cohort of 323,666 (Mayo Clin Proc 2026)Mayo Clin Proc · July 2026 7
• Lp(a) is causally linked to aortic aneurysm risk by Mendelian randomisation, UK Biobank cohort of 312,332 (J Clin Lipidol 2026)J Clin Lipidol · July 2026 7
• Lp(a) of 30 mg/dL or more predicts CKD progression and cardiovascular death, nationwide Chinese cohort study (J Clin Lipidol 2026)J Clin Lipidol · July 2026 7
• Adding Lp(a) nearly doubles lipid-lowering-treatment eligibility in a 24,994-person primary-prevention cohort, SCAPIS (Atherosclerosis 2026)Atherosclerosis · June 2026 7
• Lp(a) raises post-PCI cardiovascular risk mainly when pericoronary inflammation is high, machine-learning study (J Clin Lipidol 2026)J Clin Lipidol · June 2026 7
• Phenotypic clustering splits high-Lp(a) patients into distinct cardiovascular risk groups, cohort of 2,355 (Sci Rep 2026)Sci Rep · May 2026 7
• Comparative associations of LDL-C, Lp(a), hsCRP, and IL-6 with cardiovascular risk: Insights from the UK Biobank and MESAProg Cardiovasc Dis · May 2026 7
• Adding LAA morphology and Lp(a) to a thrombus-risk model beats CHA2DS2-VA in atrial fibrillation, cohort of 418 (Int J Cardiol Heart Vasc 2026)Int J Cardiol Heart Vasc · May 2026 7
• Lp(a) mortality risk varies by race and ethnicity in NHANES III, 22.6-year mean follow-up (Am J Cardiol 2026)Am J Cardiol · May 2026 7
• Elevated Lp(a) raises restenosis risk 3-fold after PCI, meta-analysis of twenty-six studies (J Clin Med 2026)J Clin Med · April 2026 7
• Lp(a) concentration and fewer KIV-2 repeats each independently predict MI risk in China, INTERHEART China study of 4,479 (Lipids Health Dis 2026)Lipids Health Dis · April 2026 7
• Lipoprotein(a), High-Sensitivity C-Reactive Protein, and Incident ASCVD Risk in Individuals Without Standard Modifiable Risk FactorsEur J Prev Cardiol · April 2026 7
• Lp(a) raises heart failure risk in a nonlinear, plateauing dose-response pattern, meta-analysis of 400,631 (Clin Cardiol 2026)Clin Cardiol · April 2026 7
• Menopause transition triggers a fourfold larger Lp(a) rise than staying pre- or postmenopausal, UK Biobank preprint of 4,562 women (medRxiv 2026)medRxiv · March 2026 7
• Elevated Lp(a) raises repeat revascularisation risk after PCI, meta-analysis of eighteen studies (Acta Cardiol 2026)Acta Cardiol · March 2026 7
• Lp(a) of 50 mg/dl or more raises recurrent MACE risk 82.6% in very young acute coronary syndrome survivors, STudy of eArly Myocardial INfArction registry (Coron Artery Dis 2026)Coron Artery Dis · March 2026 7
• Lp(a) variability after ACS mainly reclassifies intermediate-risk patients, cohort of 235 (J Clin Med 2026)J Clin Med · March 2026 7
• Linear and Nonlinear Associations Between Lipoprotein(a) and the Risks of Atherosclerotic Cardiovascular DiseaseCirc J · February 2026 7
• Lp(a) and insulin resistance jointly raise cardiovascular risk 32%, UK Biobank cohort of 328,031 (J Am Heart Assoc 2026)J Am Heart Assoc · February 2026 7
• Elevated Lp(a) independently predicts stenotic bioprosthetic valve degeneration, cohort of 174 (Eur Heart J Cardiovasc Imaging 2026)Eur Heart J Cardiovasc Imaging · February 2026 7
• Time-weighted Lp(a) outpredicts single-measurement Lp(a) for calcific aortic valve disease, cohort of 5,156 (Lipids Health Dis 2026)Lipids Health Dis · February 2026 7
• Lp(a) 50 mg/dL or more raises intracranial stenosis odds 4.5-fold in ischemic stroke, cohort of 397 (J Clin Lipidol 2026)J Clin Lipidol · January 2026 7
• Lp(a) varies little within individuals, repeat testing rarely needed, cohort of 250 (J Clin Lipidol 2026)J Clin Lipidol · January 2026 7
• Elevated Lp(a) predicts mortality only in high traditional cardiovascular risk, NHANES III cohort with follow-up to 2019 (Eur J Prev Cardiol 2026)Eur J Prev Cardiol · January 2026 7
• Dual-high Lp(a) and inflammatory-lipid index carries an 8-fold MACE risk in 1,910 ACS patients with type 2 diabetes (Front Cardiovasc Med 2026)Front Cardiovasc Med · January 2026 7
• High Lp(a) plus high homocysteine triples MACE risk after premature myocardial infarction in a 1,741-patient cohort, validating a '50-15' dual threshold (Front Nutr 2026)Front Nutr · January 2026 7
• Elevated Lp(a) improves 20-year ASCVD risk reclassification beyond HellenicSCOREII+, two Greek cohorts (J Clin Lipidol 2026)J Clin Lipidol · December 2025 7
• Lp(a) above 50 mg/dL predicts MACE and improves SCORE2/PCE performance, ambulatory cohort of 3,052 (Clin Res Cardiol 2026)Clin Res Cardiol · December 2025 7
• Phenotypic clustering splits high-Lp(a) patients into four ASCVD-risk subgroups, RED-CARPET study of 11,629 (Clin Res Cardiol 2026)Clin Res Cardiol · June 2025 7
• Lp(a) 30 mg/dL or more predicts cardiovascular death or HF hospitalization, cohort of 1,088 (J Card Fail 2026)J Card Fail · April 2025 7
• Adding Lp(a) to an EHR-based ASCVD risk score reclassifies 21.3% of borderline-risk patients (Circ Genom Precis Med 2025)Circ Genom Precis Med · January 2025 7
• A random survival forest model beats traditional risk scores at predicting cardiovascular events in 4,369 patients with measured Lp(a) (Circ Genom Precis Med 2025)Circ Genom Precis Med · January 2025 7
• Elevated apoB is needed for high Lp(a) to raise ASCVD risk in the ARIC study (Am Heart J 2025)Am Heart J · December 2024 7
• Lipoprotein(a) interacts with albuminuria, not eGFR, to raise chronic kidney disease risk in 329,415 UK Biobank participants (JMIR Public Health Surveill 2024)JMIR Public Health Surveill · January 2024 7
• Combining Lp(a) and fibrinogen improves all-cause mortality prediction in 43,367 coronary artery disease patients (Technol Health Care 2024)Technol Health Care · January 2024 7
• Lp(a) improves 20-year cardiovascular risk reclassification beyond the Framingham and Reynolds scores, the ATTICA study (J Clin Lipidol 2024)J Clin Lipidol · January 2024 7
• Elevated Lp(a) independently predicts major adverse cardiovascular events and mortality after acute coronary syndrome, a meta-analysis of 18,168 patients (Front Cardiovasc Med 2024)Front Cardiovasc Med · January 2024 7
• Extended dual antiplatelet therapy beyond 1 year cuts ischaemic events in ACS patients with elevated Lp(a), but not those with normal Lp(a), in 4,357 PCI patients (Cardiol J 2024)Cardiol J · October 2023 7
• Adding Lp(a) to the Pooled Cohort Equations meaningfully improves 10-year ASCVD risk reclassification, especially in low-risk individuals, in 6,639 MESA participants (Atherosclerosis 2023)Atherosclerosis · August 2023 7
• Lp(a) and its oxidised phospholipids predict multivessel coronary disease and cardiovascular events in 1,098 patients undergoing angiography, the CASABLANCA study (J Am Coll Cardiol 2023)J Am Coll Cardiol · May 2023 7
• Lp(a) testing is performed in only 0.34% of German patients, but when done, is linked to better cardiovascular outcomes, an analysis of 4 million claims records (Atherosclerosis 2023)Atherosclerosis · January 2023 7
• Elevated Lp(a) (>30 mg/dL) raises long-term MACE risk by 31% after PCI for in-stent restenosis, in 2,086 patients (J Clin Lipidol 2023)J Clin Lipidol · January 2023 7
• High Lp(a) doubles coronary heart disease risk only in people with elevated Factor VIII or hs-CRP, an interaction found in 6,495 MESA participants (J Clin Lipidol 2023)J Clin Lipidol · January 2023 7
• Unlike LDL-C, Lp(a) is not associated with baseline coronary artery calcium and only modestly predicts its progression, in 5,597 MESA participants (J Clin Lipidol 2023)J Clin Lipidol · January 2023 7
• Every 10 mg/dL rise in Lp(a) raises peripheral artery disease risk by 6%, a dose-response meta-analysis of 565,209 people across 68 studies (Eur J Med Res 2022)Eur J Med Res · November 2022 7
• Elevated Lp(a) raises cardiac event risk only when hs-CRP is also high, an interaction found in 10,424 PCI patients (Atherosclerosis 2022)Atherosclerosis · October 2022 7
• Elevated Lp(a) (>=50 mg/dL) raises coronary heart disease risk regardless of LDL-C level, in 4,585 MESA participants (Atherosclerosis 2022)Atherosclerosis · October 2022 7
• A common LPA gene variant only raises Lp(a) and coronary disease risk in the 96% of people who do not also carry a specific splicing mutation, a genetic study of 184,283 people (Atherosclerosis 2022)Atherosclerosis · April 2022 7
• Elevated Lp(a) raises limb amputation risk more than 20-fold in peripheral artery disease, a systematic review of 493,650 subjects across 15 studies (Vasc Med 2022)Vasc Med · April 2022 7
• Elevated Lp(a) plus a coronary calcium score of 100+ carries a 4.7-fold higher cardiovascular risk than either alone, in MESA and Dallas Heart Study participants (J Am Coll Cardiol 2022)J Am Coll Cardiol · March 2022 7
• A single Lp(a) measurement suffices for CAD risk prediction, since repeat levels stay 96% correlated over years, in 16,017 UK Biobank participants (J Am Coll Cardiol 2022)J Am Coll Cardiol · February 2022 7
• Lp(a) makes up 15% of all atherogenic particles at the highest Lp(a) levels, a particle-based analysis of 158,260 patients (J Clin Lipidol 2022)J Clin Lipidol · January 2022 7
• Very high Lp(a) (>100 mg/dL) predicts multivessel coronary disease and a stepwise rise in in-hospital mortality after heart attack, the French RICO survey of 1,213 patients (J Clin Lipidol 2022)J Clin Lipidol · January 2022 7
• Lp(a) predicts coronary disease and its severity across ethnicities, highest in Asian Indians, in a multi-ethnic study of 2,025 Southeast Asian patients (Atherosclerosis 2022)Atherosclerosis · November 2021 7
• Lp(a) in the top quartile raises subclinical coronary plaque odds by up to 67%, in 7,201 asymptomatic individuals undergoing CT angiography (Atherosclerosis 2022)Atherosclerosis · September 2021 7
• Lp(a)-related cardiovascular risk only appears when hs-CRP is also elevated, a MESA analysis of 4,679 participants (J Am Coll Cardiol 2021)J Am Coll Cardiol · September 2021 7
• Lp(a) above 60 mg/dL is linked to greater coronary plaque volume on IVUS, a pooled analysis of 3,943 patients across 6 trials (J Am Heart Assoc 2020)J Am Heart Assoc · November 2020 7
• Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE TrialJAMA Cardiol · October 2020 7
• Elevated Lp(a) and family history combine for a 43% higher cardiovascular risk than either alone, in 12,149 ARIC participants (J Am Coll Cardiol 2020)J Am Coll Cardiol · August 2020 7
• Lp(a) matches LDL as a cause of heart attacks but outweighs it for mortality risk, a head-to-head comparison in about 100,000 Danes (Curr Opin Lipidol 2020)Curr Opin Lipidol · June 2020 7
• High Lp(a) independently raises cardiovascular mortality risk in 1492 peritoneal dialysis patients (J Clin Lipidol 2020)J Clin Lipidol · January 2020 7
• 1 in 7 Americans has Lp(a) above the risk threshold, and Lp(a) predicts heart attack but not stroke in a nationally representative cohort of 8214 (J Clin Lipidol 2020)J Clin Lipidol · January 2020 7
• Higher Lp(a) predicts cardiovascular events in 393 Chinese patients with familial hypercholesterolaemia despite statin treatment (Atherosclerosis 2019)Atherosclerosis · October 2019 7
• Lp(a) in the highest tertile raises stroke risk by 34% in a prospective cohort of 8500 Chinese adults (Atherosclerosis 2019)Atherosclerosis · July 2019 7
• Four Lp(a)-associated gene variants predict more severe coronary disease in 1403 Han Chinese patients, a genome-wide association study (J Lipid Res 2019)J Lipid Res · June 2019 7
• Lp(a) predicts additional cardiovascular risk in people with diabetes or prediabetes, the ARIC study of 9,871 adults (Atherosclerosis 2019)Atherosclerosis · December 2018 7
• Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical TrialJAMA Cardiol · February 2018 7
• Elevated Lp(a) and LDL together predict the most severe coronary lesions in young patients with premature coronary disease, a study of 147 patients (J Clin Lipidol 2018)J Clin Lipidol · January 2018 7
• Inflammatory IL-1 genotype doubles the cardiovascular risk from high Lp(a), the Ioannina Study of 603 patients (J Clin Lipidol 2018)J Clin Lipidol · December 2017 7
• High Lp(a) predicts aortic valve surgery only in patients who also have coronary artery disease, a Swedish study of 336 surgical cases (J Am Heart Assoc 2017)J Am Heart Assoc · December 2017 7
• Elevated Lp(a) triples acute coronary syndrome risk in adults under 45, but the link fades after 60, a case-control study of 1457 ACS patients (Atherosclerosis 2018)Atherosclerosis · December 2017 7
• Lp(a) does not predict coronary plaque progression during intensive statin therapy, a SATURN substudy of 915 patients (Atherosclerosis 2017)Atherosclerosis · June 2017 7
• Lp(a) predicts heart failure hospitalization, but the link disappears once prior heart attacks are excluded, the ARIC study of 14,154 adults (Atherosclerosis 2017)Atherosclerosis · May 2017 7
• Low Lp(a) below 7 mg/dL, not high Lp(a), raises type-2 diabetes risk, the Bruneck study combined with a meta-analysis of 74,575 people (Cardiovasc Diabetol 2017)Cardiovasc Diabetol · March 2017 7
• Lp(a) and familial hypercholesterolaemia together predict early, severe coronary disease, a Chinese angiography cohort of 8050 patients (Atherosclerosis 2017)Atherosclerosis · March 2017 7
• Coronary disease risk rises at Lp(a) levels below the standard 50 mg/dL threshold, an EPIC-Norfolk study of 623 cases and 948 controls across two assays (J Lipid Res 2016)J Lipid Res · January 2016 7
• High Lp(a) marks vulnerable, lipid-rich coronary plaques in acute coronary syndrome, an imaging study of 500 angiographic and 51 OCT patients (Atherosclerosis 2016)Atherosclerosis · January 2016 7
• Lp(a) predicts diabetic retinopathy, with a five-fold higher risk when combined with poor glucose control, a prospective cohort of 787 patients with type 2 diabetes (J Clin Lipidol 2016)J Clin Lipidol · January 2016 7
• Lp(a) raises ischemic stroke risk by about a third, especially in younger patients, a meta-analysis of 20 studies and 90,904 subjects (Atherosclerosis 2015)Atherosclerosis · August 2015 7
• High familial Lp(a) impairs blood vessel function in children, an effect blunted by early dietary intervention, the Finnish STRIP study at age 11 (J Pediatr 2015)J Pediatr · February 2015 7
• In people with type 2 diabetes, genetically high Lp(a) does not raise cardiovascular risk, unlike in the general population, a GWAS of 2308 diabetic patients (Eur Heart J 2012)Eur Heart J · September 2011 7
• High Lp(a) independently predicts polyvascular disease in patients undergoing bypass surgery, a Korean study of 470 patients (Atherosclerosis 2011)Atherosclerosis · June 2011 7
• The highest Lp(a) quartile raises the risk of combined intracranial and extracranial artery narrowing five-fold in stroke patients, a Korean study of 1012 patients (Atherosclerosis 2010)Atherosclerosis · July 2010 7
• Lp(a), not fibrinogen, independently predicts coronary plaque progression on serial imaging, a study of 60 left main coronary arteries (J Am Coll Cardiol 2006)J Am Coll Cardiol · July 2006 7
• High CRP or Lp(a), but not homocysteine, predict adverse events after coronary stenting, a study of 483 patients followed 3 years (J Am Coll Cardiol 2002)J Am Coll Cardiol · October 2002 7
• Adjusting the Friedewald LDL formula for Lp(a) does not improve heart disease risk prediction, the Quebec Cardiovascular Study of 2222 men (Atherosclerosis 2002)Atherosclerosis · August 2002 7
• Elevated Lp(a) does not predict restenosis or cardiac events after coronary angioplasty, a FLARE trial analysis of 823 patients (Atherosclerosis 2001)Atherosclerosis · October 2001 7
• Lp(a) predicts intermittent claudication more strongly in women than men, the Edinburgh Artery Study of 1592 adults (Atherosclerosis 2001)Atherosclerosis · July 2001 7
• Lp(a) does not predict peripheral artery disease, unlike CRP and the cholesterol ratio, a study of 14,916 physicians (JAMA 2001)JAMA · May 2001 7
• Elevated Lp(a) unexpectedly raises coronary risk in older women just as strongly as in younger men, a cohort of 918 CAD and 829 non-CAD patients (Atherosclerosis 2000)Atherosclerosis · December 2000 7
• Lp(a) predicts prior heart attack in patients with coronary spasm, a Japanese study across three patient groups (J Am Coll Cardiol 2000)J Am Coll Cardiol · April 2000 7
• A newer Lp(a)-cholesterol assay adds no predictive value over standard Lp(a) mass testing, a WOSCOPS nested case-control study of 238 controls and 108 cases (Atherosclerosis 2000)Atherosclerosis · January 2000 7
• Elevated Lp(a)-to-HDL-C ratio predicts repeat revascularization and in-stent restenosis after PCI in chronic coronary syndrome (Biomark Med 2026)Biomark Med · September 2026 6
• GAELp(a) registry shows conventional apoB underestimates weighted atherogenic burden by a median 34.7 percentile points at Lp(a) ≥300 nmol/L (Atherosclerosis 2026)Atherosclerosis · August 2026 6
• Intraindividual lipoprotein(a) variability exceeds 20% in 51% of pediatric patients, with risk reclassification concentrated near decision thresholds (J Clin Lipidol 2026)J Clin Lipidol · August 2026 6
• Lp(a) predicts ASCVD, coronary disease and prior MI but not stroke, 23,654-person Polish real-world cohort (J Clin Lipidol 2026)J Clin Lipidol · July 2026 6
• Elevated Lp(a) raises cardiovascular death risk 51% after successful CTO-PCI, 1509-patient cohort (J Cardiovasc Dev Dis 2026)J Cardiovasc Dev Dis · July 2026 6
• Preoperative Lp(a) of 30 mg/dL or more doubles 1-year stroke risk after intracranial stenting, 405-patient registry (Neurologist 2026)Neurologist · July 2026 6
• Lp(a) of 75 nmol/L or more predicts worse neurological outcome after ischemic stroke, Spanish cohort of 300 (Clin Investig Arterioscler 2026)Clin Investig Arterioscler · May 2026 6
• Lp(a) and inflammation (CAR) jointly predict poor 90-day outcome after stroke in elderly patients, cohort of 732 (Lipids Health Dis 2026)Lipids Health Dis · May 2026 6
• Lp(a) above 31.2 mg/dL raises poor 3-month stroke outcome risk 79%, cohort of 175 (Brain Behav 2026)Brain Behav · May 2026 6
• Elevated Lp(a) predicts higher 6-month MACE risk after myocardial infarction, Bosnian cohort of 150 (Med Sci Basel 2026)Med Sci (Basel) · April 2026 6
• High Lp(a) raises AMI risk most in older women, case-control study of 2,946 patients (J Int Med Res 2026)J Int Med Res · April 2026 6
• Lp(a) tracks coronary stenosis severity and Gensini score, Chinese angiography cohort of 778 (Rev Cardiovasc Med 2026)Rev Cardiovasc Med · April 2026 6
• High Lp(a) predicts worse outcomes but poor discrimination after drug-eluting stent PCI, meta-analysis of 27,618 (J Clin Lipidol 2026)J Clin Lipidol · April 2026 6
• Adding Lp(a) improves pre-test probability calibration for obstructive CAD, derivation cohort of 4,262 (Eur Heart J Cardiovasc Imaging 2026)Eur Heart J Cardiovasc Imaging · March 2026 6
• Preoperative Lp(a) of 30 mg/dL or more independently predicts peri-procedural stroke after intracranial stenting (Neurol Res 2026)Neurol Res · March 2026 6
• High Lp(a) predicts worse long-term outcomes after STEMI in Japanese patients, 868-patient cohort (Circ J 2026)Circ J · March 2026 6
• Lp(a) predicts recurrent ACS despite negative fractional flow reserve testing, Chinese cohort of 513 (Rev Cardiovasc Med 2026)Rev Cardiovasc Med · March 2026 6
• Elevated Lp(a) raises MACE risk up to 4.3-fold after PCI, systematic review of 23,421 patients (Cureus 2026)Cureus · March 2026 6
• Lp(a) and an LDL subfraction synergistically predict MACE after ACS, cohort of 2,061 (Angiology 2026)Angiology · February 2026 6
• Cumulative LDL-C and Lp(a) predict coronary disease in statin-naive elderly, Turkish cohort of 202 (Turk Kardiyol Dern Ars 2026)Turk Kardiyol Dern Ars · January 2026 6
• A Kazakhstani angiographic cohort finds obstructive coronary disease risk rising at Lp(a) of just 37 nmol/L, well below Western thresholds (Front Med (Lausanne) 2026)Front Med (Lausanne) · January 2026 6
• Combining Lp(a) with the Suita score improves high-risk plaque prediction in Japanese patients, cohort of 272 (J Atheroscler Thromb 2026)J Atheroscler Thromb · December 2025 6
• Review argues coronary artery calcium and Lp(a) testing should be used together, not as alternatives, in intermediate-risk prevention (Curr Cardiol Rep 2025)Curr Cardiol Rep · February 2025 6
• A machine-learning tool (ARISE) could raise Lp(a) testing yield in health systems where only 0.4% of patients are tested (Circ Genom Precis Med 2025)Circ Genom Precis Med · January 2025 6
• New "risk-weighted apoB" metric corrects for apoB underestimating risk when Lp(a) is high, using its roughly sevenfold greater atherogenicity per particle (Lipids Health Dis 2024)Lipids Health Dis · September 2024 6
• Adding Lp(a) and three other markers to the GRACE score lifts in-hospital MACE prediction AUC from 0.81 to 0.86 in 647 heart attack patients (Int J Cardiol Cardiovasc Risk Prev 2024)Int J Cardiol Cardiovasc Risk Prev · July 2024 6
• Elevated Lp(a) (>50 mg/dL) predicts failure to reach LDL-C targets in 870 patients with stable coronary artery disease (Clin Investig Arterioscler 2024)Clin Investig Arterioscler · January 2024 6
• Elevated Lp(a) (>=30 mg/dL) more than quadruples risk of adverse cardiac events after PCI in 600 coronary artery disease patients (Indian Heart J 2024)Indian Heart J · January 2024 6
• Elevated Lp(a) predicts major adverse cardiovascular events after PCI in 1,168 patients with ischaemic heart failure, especially those with obesity (Front Cardiovasc Med 2024)Front Cardiovasc Med · January 2024 6
• 27% of 2,001 high-risk Polish patients have elevated Lp(a), the Zabrze-Lipoprotein(a) Registry first results (Arch Med Sci 2024)Arch Med Sci · January 2024 6
• The HellenicSCORE II+ improves 10-year cardiovascular risk classification by 4% when stratified by Lp(a), calibrated on the ATTICA cohort (Hellenic J Cardiol 2024)Hellenic J Cardiol · October 2023 6
• Elevated Lp(a) predicts long-term recurrent myocardial infarction but not mortality in 1,223 AMI survivors followed a median 9.9 years (Am J Cardiol 2024)Am J Cardiol · October 2023 6
• A healthy lifestyle lowers coronary artery disease risk regardless of Lp(a) level, though risk is highest with unfavourable habits and high Lp(a), in 4,512 Japanese patients (Eur J Clin Invest 2024)Eur J Clin Invest · September 2023 6
• Elevated Lp(a) raises coronary artery calcification risk by 58% in asymptomatic adults, a meta-analysis of 12 studies (Nutr Metab Cardiovasc Dis 2023)Nutr Metab Cardiovasc Dis · July 2023 6
• Elevated Lp(a) predicts cardiovascular events and death in chronic kidney disease patients, a systematic review of 12,260 individuals across 15 prospective studies (J Nephrol 2023)J Nephrol · April 2023 6
• Elevated Lp(a) triples myocardial infarction risk in young patients, a systematic review of 9 studies screened from 334 (Int J Mol Sci 2023)Int J Mol Sci · March 2023 6
• Elevated Lp(a) most robustly predicts coronary events in postmenopausal women, though results are mixed for other outcomes, a systematic review of 157,690 women (Curr Probl Cardiol 2023)Curr Probl Cardiol · January 2023 6
• High Lp(a) brings cardiovascular events about 7 years earlier than high LDL alone in polygenic hypercholesterolaemia, with sex-specific patterns, in 548 patients (Front Cardiovasc Med 2023)Front Cardiovasc Med · January 2023 6
• Elevated Lp(a) raises cognitive impairment odds by 62% and stroke-related disability by 46% in secondary prevention ASCVD patients, a systematic review of 61 studies (PLoS One 2023)PLoS One · January 2023 6
• Black individuals have the highest Lp(a) levels of any ethnicity studied, followed by South Asians, complicating a single universal risk threshold, a review (Atherosclerosis 2022)Atherosclerosis · May 2022 6
• Up to 1 billion people worldwide may have high-risk Lp(a) levels, a genetic epidemiology review spanning heart attacks to lifespan (Atherosclerosis 2022)Atherosclerosis · May 2022 6
• Elevated Lp(a) tracks with lipid-rich, vulnerable coronary plaque specifically in diabetic patients on statins, the REASSURE-NIRS registry of 312 patients (Atherosclerosis 2022)Atherosclerosis · April 2022 6
• Elevated Lp(a) predicts worse cardiac outcomes after acute coronary syndrome, most strongly in patients with chronic kidney disease, in 1,306 patients (Atherosclerosis 2022)Atherosclerosis · April 2022 6
• About 1 in 5 people has Lp(a) above 50 mg/dL, and it raises cardiovascular risk even with LDL cholesterol below 70 mg/dL, a review (J Cardiovasc Pharmacol 2022)J Cardiovasc Pharmacol · January 2022 6
• Patients with abdominal aortic aneurysm have significantly higher Lp(a) than controls, a meta-analysis of 5,078 subjects across 11 studies (Curr Pharm Des 2022)Curr Pharm Des · January 2022 6
• High Lp(a) predicts major limb events after leg artery surgery for peripheral artery disease, in 384 Dutch patients (Atherosclerosis 2022)Atherosclerosis · November 2021 6
• High Lp(a) affects 10-20% of the population and up to 1 billion people worldwide, tripling risk of aortic stenosis and peripheral artery disease, a review (Clin Chem 2021)Clin Chem · January 2021 6
• Lp(a) still predicts cardiovascular risk even when LDL-C is under 70 mg/dL, one of three residual-risk drivers alongside remnants and inflammation, a review (Clin Chem 2021)Clin Chem · January 2021 6
• Elevated Lp(a) raises hard coronary event risk by 71% in ACS patients aged 80 and older, a study of 536 elderly patients (J Clin Lipidol 2021)J Clin Lipidol · January 2021 6
• Lp(a) above 30 mg/dL raises cardiovascular death risk by 50% in AMI patients aged 80 and older, a prospective cohort of 1,008 patients (Atherosclerosis 2020)Atherosclerosis · September 2020 6
• An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER TrialJAMA Cardiol · June 2020 6
• The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous ThromboembolismCirculation · May 2020 6
• High Lp(a) (>20 mg/dL) blocks coronary plaque regression despite statin therapy after ACS, the Yokohama-ACS IVUS substudy of 76 patients (J Cardiol 2020)J Cardiol · February 2020 6
• A systematic review of 19 studies finds a moderate but inconsistent Lp(a)-cardiovascular disease association across primary and secondary prevention (Curr Opin Cardiol 2019)Curr Opin Cardiol · July 2019 6
• Elevated Lp(a) is common in patients needing coronary intervention despite controlled risk factors, but screening does not change physician treatment decisions, a study of 113 patients (J Clin Lipidol 2017)J Clin Lipidol · January 2017 6
• Lp(a) correlates with the Framingham risk score in a Brazilian cohort of 400 people, the Ouro Preto Study (Atherosclerosis 2007)Atherosclerosis · July 2006 6
• Lp(a) and ApoB/ApoA1 ratio independently predict coronary heart disease in type 2 diabetes (Lipids 2026)Lipids · September 2026 5
• Imaging for subclinical atherosclerosis aids risk stratification in patients with elevated Lp(a) (J Clin Lipidol 2026)J Clin Lipidol · September 2026 5
• 2026 multi-society guideline classifies Lp(a) ≥ 125 nmol/L as a risk-enhancing factor (J Clin Med 2026)J Clin Med · August 2026 5
• Lp(a) adds modest but real predictive value for MACE after acute coronary syndrome, 300-patient cohort (J Clin Med 2026)J Clin Med · August 2026 5
• Distribution of Lipoprotein(a) concentrations in children and young people with Familial Hypercholesterolemia (FH) compared to those without FH: A systematic review and narrative synthesisAtherosclerosis · August 2026 5
• Combining Lp(a) and severe calcification predicts limb events after endovascular therapy for PAD, 145-patient study (Heart Vessels 2026)Heart Vessels · July 2026 5
• Lp(a) and insulin resistance jointly predict atherosclerotic plaque with a U-shaped interaction, 10,753-person Chinese cohort (Lipids Health Dis 2026)Lipids Health Dis · July 2026 5
• Lp(a) predicts left ventricular dysfunction in chronic total occlusion patients, 309-patient cohort (BMC Cardiovasc Disord 2026)BMC Cardiovasc Disord · July 2026 5
• First-trimester Lp(a) predicts preeclampsia, 119-woman pilot cohort (Arch Gynecol Obstet 2026)Arch Gynecol Obstet · July 2026 5
• Improved diagnosis of familial hypercholesterolemia by correcting LDL-C for lipoprotein(a) in a German cohortJ Clin Lipidol · June 2026 5
• Polygenic risk scores and Lp(a) extend genetic risk stratification beyond monogenic hypercholesterolaemia, review (Genes Basel 2026)Genes (Basel) · June 2026 5
• Adding Lp(a) to the EAS risk score improves CHD reclassification in type 2 diabetes, pilot study of 90 (J Assoc Physicians India 2026)J Assoc Physicians India · February 2026 5
• Optimal Lp(a) cutoff for cardiovascular disease drops to 70 mg/L in diabetic patients, comparative analysis finds (Front Endocrinol (Lausanne) 2026)Front Endocrinol (Lausanne) · January 2026 5
• Lp(a) predicts post-PCI cardiac events in coronary disease and diabetes, but evidence is inconsistent, review of four studies (Am J Med Sci 2026)Am J Med Sci · December 2025 5
• Adding Lp(a) to SCORE2 reclassified most moderate-risk patients to high risk and made 61% eligible for statins, 140-subject study finds (Biomedicines 2025)Biomedicines · October 2025 5
• Adding Lp(a) and an inflammation index to the TIMI score sharpens MACE prediction after STEMI in 290 patients (Int J Cardiol Heart Vasc 2025)Int J Cardiol Heart Vasc · January 2025 5
• Combining monocyte-to-HDL ratio with Lp(a) lifts in-stent restenosis prediction to an AUC of 0.860 in 190 stented patients (Front Cardiovasc Med 2025)Front Cardiovasc Med · January 2025 5
• Lp(a) above 166.16 nmol/L flags severe coronary anatomy (SYNTAX score 23+) with 97% sensitivity in 173 heart attack patients (J Clin Med 2024)J Clin Med · November 2024 5
• Elevated Lp(a) predicts left atrial thrombus or spontaneous echo contrast in 481 atrial fibrillation patients with low CHA2DS2-VASc scores (Lipids Health Dis 2024)Lipids Health Dis · January 2024 5
• Combining Lp(a) with neck circumference improves diagnostic accuracy for coronary heart disease in 791 patients undergoing angiography (Int J Gen Med 2024)Int J Gen Med · January 2024 5
• Patients with elevated Lp(a) (>125 nmol/L) face very high cardiovascular risk, with early events in 65% of women and 56% of men, in 316 Spanish patients (Clin Investig Arterioscler 2024)Clin Investig Arterioscler · December 2023 5
• Lp(a) is moving from a passive risk marker to an active therapeutic target in acute coronary syndromes, as ASOs and siRNAs enter phase 3, a review (Curr Pharm Des 2023)Curr Pharm Des · January 2023 5
• Elevated Lp(a) drives residual cardiovascular risk even at optimal LDL-C, but proof that lowering it helps still awaits trial data, a review (J Cardiovasc Med 2021)J Cardiovasc Med (Hagerstown) · March 2021 5
• Lp(a) risk is independent of every other lipid marker, but treatment options remain scarce, a residual-risk update (Am J Cardiol 2020)Am J Cardiol · April 2020 5
• Lp(a) value for predicting recurrent events in secondary prevention remains inconsistent, a critical appraisal addressing index event bias (J Clin Lipidol 2018)J Clin Lipidol · January 2018 5
• Atellica implementation of Roche Tina-quant Lp(a) Gen.2 matches Cobas comparators; fixed conversion formulas introduce bias (J Appl Lab Med 2026)J Appl Lab Med · August 2026 4
• Lp(a) correlates with coronary disease severity (SYNTAX score, r=0.36) in an Indian angiography cohort (Ann Afr Med 2026)Ann Afr Med · July 2026 4
• Lp(a) tracks coronary complexity mainly in patients under 45 with premature MI, Northeast Indian cohort of 100 (Maedica Bucur 2026)Maedica (Bucur) · June 2026 4
• In 347 Japanese ACS patients discharged alive after primary PCI, Lp(a) of 30 mg/dL or higher did not predict mid-term MACE (Int Heart J 2026)Int Heart J · January 2026 4
• Advanced age and higher HbA1c are linked to elevated Lp(a) in 600 cardiovascular disease patients, alongside associations with MACE and stroke (Ann Card Anaesth 2024)Ann Card Anaesth · January 2024 4
• Distribution of Lipoprotein(a) Levels and Clinical Associations in a Lebanese Adult Population: A Retrospective Observational StudyJ Clin Med · February 2026 3
• Lipoprotein(a) and Cardiovascular Disease: From Genetic Risk Factor to Therapeutic TargetCells · February 2026 3
• Diagnostic and Severity Assessment of Coronary Artery Disease Using ApoB/ApoA-I Ratio: Insights from a Statin-Treated Eastern European CohortMedicina (Kaunas) · February 2026 3
• Lipoprotein(a) Concentration and Achieving Target Values of Low-Density Lipoprotein Cholesterol Calculated by Different EquationsDiseases · January 2026 3
• Clinical value of Lipoprotein(a) combined with CatLet coronary score in predicting adverse events after emergency PCI for AMI patientsPLoS One · January 2026 3